High thioredoxin reductase 1 expression in meningiomas undergoing malignant progression

Basit Öğe Kaydı
dc.contributor.authorEsen, Hasan
dc.contributor.authorFeyzioglu, Bahadir
dc.contributor.authorErdi, Fatih
dc.contributor.authorKeskin, Fatih
dc.contributor.authorKaya, Bulent
dc.contributor.authorDemir, Lutfi Saltuk
dc.date.accessioned2024-02-23T13:55:55Z
dc.date.available2024-02-23T13:55:55Z
dc.date.issued2015
dc.departmentNEÜen_US
dc.description.abstractThioredoxin (Trx) is a redox active protein that regulates several physiological and biochemical functions, such as growth, apoptosis and cellular defense. The function of Trx itself is regulated by thioredoxin reductase (TrxR). This study was designed to determine the expression of TrxR1 in meningioma tissues of different World Health Organization grades (grade I-III). Meningioma tissues were extracted from the histopathological specimens of 29 patients. These samples included seven histologically normal meningeal tissues that served as a control group and 12 grade I, 12 grade II and 5 grade III meningioma samples. TrxR1 expression was evaluated using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunostaining. The proliferative and apoptotic indices of the specimens were investigated by Ki-67 immunostaining and TUNEL assay, respectively. TrxR1 expression, as assessed by qRT-PCR, increased significantly with meningioma grade (p < 0.001). The immunostaining intensity of TrxR1 increased significantly with meningioma grade (p < 0.001). Ki-67 index values increased significantly in accordance with grade progression (p < 0.001). The apoptotic index values were not significantly different in any group (p > 0.05). Trx system seems to be involved in the malignant progression of meningiomas. Further, large studies are required to elucidate the exact role of this system.en_US
dc.identifier.doi10.1007/s10014-015-0212-x
dc.identifier.endpage201en_US
dc.identifier.issn1433-7398
dc.identifier.issn1861-387X
dc.identifier.issue3en_US
dc.identifier.pmid25592259en_US
dc.identifier.scopus2-s2.0-84937970938en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage195en_US
dc.identifier.urihttps://doi.org/10.1007/s10014-015-0212-x
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11014
dc.identifier.volume32en_US
dc.identifier.wosWOS:000358086700006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Japan Kken_US
dc.relation.ispartofBrain Tumor Pathologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMeningiomaen_US
dc.subjectTrxr1en_US
dc.subjectExpressionen_US
dc.subjectApoptosisen_US
dc.subjectProliferationen_US
dc.subjectGradeen_US
dc.titleHigh thioredoxin reductase 1 expression in meningiomas undergoing malignant progressionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu